United States: WilmerHale Reps Nabriva Therapeutics In $80M Public Offering Of Ordinary Shares
Last Updated: October 5 2017

On September 22, 2017, Nabriva Therapeutics plc (NASDAQ:NBRV) closed on its underwritten public offering of 9,411,765 ordinary shares at a public offering price of $8.50 per share, totaling approximately $80 million.

Brian Johnson led the WilmerHale team representing Nabriva in this transaction, which also included Scott Lunin and Alicia Lee.

Nabriva's announcement regarding the pricing of this offering can be found at www.nabriva.com.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

 
Some comments from our readers…
“The articles are extremely timely and highly applicable”
“I often find critical information not available elsewhere”
“As in-house counsel, Mondaq’s service is of great value”

Press Releases from this Firm
Recent Content from this Firm
By Lloyd Firth
By Mark Ford, Peter Spaeth, Holly Ovington
By WilmerHale
By Gregory Lantier, Brittany Amadi
By Anna Gaudoin
By WilmerHale
By WilmerHale
By WilmerHale
By WilmerHale
By Nicolette Anagnos
Tools
Print
Font Size:
Translation
Channels